Wordt geladen...
FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has been identified for predicting sensitivity to regorafenib. Here, we investigated preclinical activity of regorafenib in gastric and colorectal c...
Bewaard in:
| Gepubliceerd in: | Mol Oncol |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6026866/ https://ncbi.nlm.nih.gov/pubmed/29573334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12194 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|